{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:46:15Z","timestamp":1786959975031,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.xops.2024.100492","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T06:01:34Z","timestamp":1707804094000},"page":"100492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation"],"prefix":"10.1016","volume":"4","author":[{"given":"Thomas H.","family":"Dohlman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan Bir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Amparo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Carreno-Galeano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Dastjerdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Coco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Zazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasanain","family":"Shikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujwala","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Sippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ciralsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia H.","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus","family":"Sticca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tais H.","family":"Wakamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somasheila","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Hamrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ula","family":"Jurkunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Ciolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajirah","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.P.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5732-5100","authenticated-orcid":false,"given":"Reza","family":"Dana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2024.100492_bib1","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.xops.2024.100492_bib2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ophtha.2023.03.012","article-title":"Global trends in blindness and vision impairment resulting from corneal opacity 1984-2020: a meta-analysis","volume":"130","author":"Wang","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100492_bib3","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2214-109X(20)30425-3","article-title":"Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study","volume":"9","author":"Bourne","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.xops.2024.100492_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108152","article-title":"Animal models of high-risk corneal transplantation: a comprehensive review","volume":"198","author":"Singh","year":"2020","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2024.100492_bib6","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bjophthalmol-2020-316705","article-title":"Corneal graft failure: an update","volume":"105","author":"Alio","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100492_bib7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2022.03.024","article-title":"Bevacizumab in high-risk corneal transplantation: a pilot multicenter prospective randomized control trial","volume":"129","author":"Dohlman","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100492_bib8","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.4049\/jimmunol.1600251","article-title":"Alloimmunity and tolerance in corneal transplantation","volume":"196","author":"Amouzegar","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xops.2024.100492_bib9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.it.2017.11.007","article-title":"When clarity is crucial: regulating ocular surface immunity","volume":"39","author":"Foulsham","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.xops.2024.100492_bib10","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ophtha.2010.01.039","article-title":"Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis","volume":"117","author":"Bachmann","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100492_bib11","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1097\/TP.0b013e3181903b0a","article-title":"Risk factors for human corneal graft failure within the Australian corneal graft registry","volume":"86","author":"Williams","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.xops.2024.100492_bib12","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1167\/iovs.15-17551","article-title":"Graft site microenvironment determines dendritic cell trafficking through the CCR7-CCL19\/21 axis","volume":"57","author":"Hua","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100492_bib13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00003226-200307000-00008","article-title":"Outcomes of repeat penetrating keratoplasty and risk factors for graft failure","volume":"22","author":"Weisbrod","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2024.100492_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archopht.126.1.71","article-title":"Promotion of graft survival by vascular endothelial growth factor A neutralization after high-risk corneal transplantation","volume":"126","author":"Bachmann","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2024.100492_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.preteyeres.2013.01.001","article-title":"Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases","volume":"34","author":"Bock","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2024.100492_bib16","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1097\/ICO.0000000000002736","article-title":"Cutting edge: novel treatment options targeting corneal neovascularization to improve high-risk corneal graft survival","volume":"40","author":"Cursiefen","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2024.100492_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109007","article-title":"Immune regulation of the ocular surface","volume":"218","author":"Chen","year":"2022","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2024.100492_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000099253","article-title":"Immune privilege and angiogenic privilege of the cornea","volume":"92","author":"Cursiefen","year":"2007","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.xops.2024.100492_bib19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang","year":"2012","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.xops.2024.100492_bib20","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","article-title":"Topical ranibizumab as a treatment of corneal neovascularization","volume":"32","author":"Ferrari","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2024.100492_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108363","article-title":"Corneal neovascularization","volume":"202","author":"Nicholas","year":"2021","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2024.100492_bib22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1634\/theoncologist.2012-0003","article-title":"Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer","volume":"17","author":"Strickler","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.xops.2024.100492_bib23","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2174\/092986706777585059","article-title":"Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic","volume":"13","author":"Ranieri","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.xops.2024.100492_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-03952-y","article-title":"VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer","volume":"12","author":"Chionh","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2024.100492_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/jamaophthalmol.2022.6142","article-title":"Cost-effectiveness of aflibercept monotherapy vs bevacizumab first followed by aflibercept if needed for diabetic macular edema","volume":"141","author":"Hutton","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2024.100492_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3341\/kjo.2022.0109","article-title":"Comparison of optical coherence tomography biomarkers between bevacizumab good responders and nonresponders who were switched to dexamethasone implant in diabetic macular edema","volume":"37","author":"Lee","year":"2023","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100492_bib27","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL noninferiority randomized trial","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100492_bib28","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.ophtha.2012.05.016","article-title":"Bevacizumab for neovascular age-related macular degeneration in China","volume":"119","author":"Li","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100492_bib29","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1111\/aos.12119","article-title":"Missotten T. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks","volume":"91","author":"Lushchyk","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2024.100492_bib30","first-page":"2326","article-title":"Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization","volume":"15","author":"Dratviman-Storobinsky","year":"2009","journal-title":"Mol Vis"},{"key":"10.1016\/j.xops.2024.100492_bib31","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100492_bib32","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/ICO.0b013e3181ba0ae2","article-title":"Corneal graft surgery combined with subconjunctival bevacizumab (Avastin)","volume":"29","author":"Symes","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2024.100492_bib33","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.jcrs.2007.07.012","article-title":"Subconjunctival bevacizumab for vascularized rejected corneal grafts","volume":"33","author":"Awadein","year":"2007","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.xops.2024.100492_bib34","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1097\/TXD.0000000000000894","article-title":"Risk of corneal graft rejection after high-risk keratoplasty following fine-needle vessel coagulation of corneal neovascularization combined with bevacizumab: a pilot study","volume":"5","author":"Hos","year":"2019","journal-title":"Transplant Direct"},{"key":"10.1016\/j.xops.2024.100492_bib35","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/ICO.0b013e31823f8f7a","article-title":"Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs","volume":"31","author":"Koenig","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2024.100492_bib36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10792-014-9938-4","article-title":"Subconjunctival and\/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival","volume":"35","author":"Fasciani","year":"2015","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.xops.2024.100492_bib37","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.4103\/ijo.IJO_1583_18","article-title":"Subconjunctival bevacizumab and argon laser photocoagulation for preexisting neovascularization following deep lamellar anterior keratoplasty","volume":"67","author":"Lakshmipathy","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100492_bib38","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/ICO.0b013e318180e50f","article-title":"Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery","volume":"27","author":"Gerten","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2024.100492_bib39","doi-asserted-by":"crossref","first-page":"NP48","DOI":"10.1177\/1120672120939504","article-title":"Long-term topical bevacizumab for prevention of corneal graft rejections","volume":"31","author":"Kuo","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100492_bib40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00417-014-2851-8","article-title":"Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab","volume":"253","author":"Dekaris","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2024.100492_bib41","first-page":"1256","article-title":"Efficacy of sub-conjunctival and topical bevacizumab in high-risk corneal transplant survival","volume":"63","author":"Bhatti","year":"2013","journal-title":"J\u00a0Pak Med Assoc"},{"key":"10.1016\/j.xops.2024.100492_bib42","first-page":"519","article-title":"Efficacy of topical bevacizumab in high-risk corneal transplant survival","volume":"29","author":"Bhatti","year":"2013","journal-title":"Pak JMed Sci"},{"key":"10.1016\/j.xops.2024.100492_bib43","article-title":"Treatment of corneal neovascularization using anti-VEGF bevacizumab","volume":"2014","author":"Krizova","year":"2014","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.xops.2024.100492_bib44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/ICL.0000000000000709","article-title":"Subconjunctival aflibercept for the treatment of formed corneal neovascularization","volume":"47","author":"Sella","year":"2021","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.xops.2024.100492_bib45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.exer.2016.03.021","article-title":"Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model","volume":"146","author":"Sella","year":"2016","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2024.100492_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/09603271221084674","article-title":"The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization","volume":"41","author":"Eski","year":"2022","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.xops.2024.100492_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1755-3768.2012.02525.x","article-title":"Topical ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis","volume":"92","author":"Bucher","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2024.100492_bib48","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/019262339902700507","article-title":"Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and fab antibodies in rhesus monkeys following intravitreal administration","volume":"27","author":"Mordenti","year":"1999","journal-title":"Toxicol Path"},{"key":"10.1016\/j.xops.2024.100492_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/tvst.6.4.13","article-title":"Evaluating changes in ocular redness using a novel automated method","volume":"6","author":"Amparo","year":"2017","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2024.100492_bib50","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1167\/iovs.13-12217","article-title":"The ocular redness index: a novel automated method for measuring ocular injection","volume":"54","author":"Amparo","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914524000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914524000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T15:37:05Z","timestamp":1721057825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914524000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2666914524000289"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2024.100492","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2024.100492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100492"}}